|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-1-4
|
|
pubmed:abstractText |
The aim of this study was to evaluate the pharmacogenetic role of the factor XIII (FXIII) valine 34 leucine (Val34Leu) polymorphism in the fibrinolytic therapy of acute myocardial infarction (MI).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0735-1097
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
45
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
25-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15629368-Aged,
pubmed-meshheading:15629368-Factor XIII,
pubmed-meshheading:15629368-Female,
pubmed-meshheading:15629368-Genotype,
pubmed-meshheading:15629368-Humans,
pubmed-meshheading:15629368-Leucine,
pubmed-meshheading:15629368-Male,
pubmed-meshheading:15629368-Middle Aged,
pubmed-meshheading:15629368-Multivariate Analysis,
pubmed-meshheading:15629368-Myocardial Infarction,
pubmed-meshheading:15629368-Polymorphism, Genetic,
pubmed-meshheading:15629368-Risk Factors,
pubmed-meshheading:15629368-Thrombolytic Therapy,
pubmed-meshheading:15629368-Valine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction.
|
|
pubmed:affiliation |
Cardiology Department, Hospital General Universitario, Alicante, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
